Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.47 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | STS | P08842 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21150756 | 0.79 | GPR119 (0.37) | GPR119TP53KDM4EMAPT | |
| SCHEMBL21150805 | 0.78 | YAP1 (0.46) | KDM4EMAPT | |
| SCHEMBL12511957 | 0.77 | NAMPT (0.53) | GPR119TP53KDM4EPKMMAPT | |
| SCHEMBL4224097 | 0.76 | GPR119 (0.58) | GPR119TP53KDM4EPKMMAPT | |
| SCHEMBL2959519 | 0.75 | GPR119 (0.74) | GPR119KDM4EMAPTTHRB | |
| SCHEMBL21152121 | 0.75 | ALDH1A1 (0.52) | TP53KDM4EPKMMAPTPOLB | |
| SCHEMBL3098616 | 0.74 | TP53 (0.51) | GPR119TP53KDM4EPKMNAMPT | |
| SCHEMBL14334645 | 0.74 | GPR119 (0.59) | GPR119TP53KDM4EPKMMAPT | |
| SCHEMBL21150819 | 0.74 | TP53 (0.67) | GPR119USP30TP53KDM4EPKM | |
| SCHEMBL21150753 | 0.73 | GRM4 (0.46) | POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-02-07 | — | — | US | disclosed |
| WO-2019136442-A1 | CD16A BINDING AGENTS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. (US) | 2019-07-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11572370-B2 | CD16A binding agents and uses thereof | FCGR1A, FCGR2A, FCGR3B | GPR119 926/4885USP30 4473/4885TP53 138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.